An estimate of the absolute pulmonary deposition of nebulised pentamidine isethionate was obtained in nine patients with AIDS. Two nebuliser systems were compared, System 22 Mizer (Medic-Aid) and Respirgard II (Marquest), with 50 and 150 mg doses of pentamidine in a 3 ml solution driven by an air flow of 6 l/min with the patient in the sitting position. The 50 mg pentamidine dose was repeated with a 6 ml fill with both devices. The nebuliser cloud was labelled with technetium-99m human serum albumin (Ventocol) and lung deposition was measured with a gamma camera. Of the two nebulisers studied, System 22 Mizer delivered more drug to the lungs as a whole and to each individual lung region, including the peripheral and upper zones. For the 50 mg dose the mean (SEM) total pulmonary deposition with the 3 and the 6 ml fill respectively was 2-63 (0 34) and 3-71 (0-41) mg The administration of antimicrobial agents via the respiratory tract has been successful in the treatment of lung infections.l" Nebulised pentamidine isethionate is effective in the treatment of acute Pneumocystis carinii pneumonia and in the suppression of disease recurrence. In centres conducting clinical trials of nebulised pentamidine to treat pneumocystis pneumonia or as prophylaxis against it the nebuliser system, dose of pentamidine, and volume of nebuliser fill have varied.57 As the therapeutic benefit of nebulised pentamidine is assumed to depend on local deposition in the lungs, the amount reaching different parts of the lung must be measured before we can interpret the results of clinical studies.
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Many factors alter pulmonary aerosol deposition. The output of a nebuliser varies with the flow rate of the driving gas, the volume of solution used, and the drug concentration and temperature of the solution being nebulised; measurements of the dose of drug in the nebuliser cloud, however, will not reliably predict the dose of drug reaching and remaining in the lungs because this may be altered by the respiratory pattern of the patient and by the inhalation apparatus. It will not be surprising if trials of nebulised pentamidine using different nebulisers, doses, and operating conditions produce different results, and these can be interpreted only when measurements of pentamidine deposition in the lung have been made.
In The total outputs (cloud recovery) of four System 22 and four Respirgard II nebuliser units were measured with 99mTc HSA by nebulising the solution to dryness. This was performed with 3 and 6 ml volumes for the 50 mg dose of pentamidine. The nebuliser cloud was captured with a pre-impinger, which is a coarse filter for removing larger particles, and an "absolute" filter, which removes the smaller particles. The total quantity of pentamidine in the nebuliser cloud was determined by washing the pre-impinger and absolute filters with known quantities of distilled water and measuring the absorbance (wavelength 266 nm) of this solution, diluted in such a way that the absorbance did not saturate the spectrometer. Previous investigations have shown absorbance to be linearly related to pentamidine concentration, and the absorbance of a 1% solution measured in a 1 cm silicon cuvette was 469. 6.12 In each study the patients remained seated with their backs to a gamma camera (large field of view IGE Maxi II) with a high sensitivity collimator for the 20 (3 ml fill) or 40 min (6 ml fill) period of aerosol inhalation. Movement of the patient was prevented by using a fixed seat with side restraints preventing lateral movement, and by fixing the position of the nebuliser mouthpiece in the midline of the gamma camera. Dynamic pulmonary deposition (posteroanterior view) was Table I Nebuliser activity before and after nebulisation: mean (SEM) resultsfrom nine experiments 
Results
The 99mTc remained bound to the human serum albumin in the pentamidine solution and in the aerosol cloud (less than 2% free technetium). The mass median diameters of particles produced by the System 22 Mizer and Respirgard II respectively were 3-7 (span 2-0) ,um and 2-0 (1-6) im with the 3 ml nebuliser volume, and 3-6 (1 9) 1m and 2-2 (1 6) um with the 6 ml volume. When expressed as a percentage of the nominal nebuliser dose (50 mg) cloud recovery for the 3 and 6 ml volumes respectively was 40% (SEM 3%) and 61% (1/%) for the System 22 Mizer and 28% (3%) and 32% (I%) for the Respirgard II. tp < 0-05 for 3 ml v 6 ml volume in nebuliser with the same dose and nebuliser. :p < 0-05 for 3 ml v 6 ml in nebuliser with the same dose and nebuliser.
Non-pulmonary deposition of pentamidine is shown in table 3. Deposition in the stomach and oropharynx was larger with the System 22 Mizer for both doses of pentamidine (p < 0-01). Deposition on the inhalation apparatus (excluding the nebuliser itself) was greater for Respirgard II (p < 0 001), with most activity located in the region of the inspiratory valve. For the System 22 Mizer, increasing the volume in the nebuliser from 3 to 6 ml increased deposition in the stomach and oropharynx, but even so local adverse effects (cough and burning in the throat) were less troublesome. Deposition in the exhalation filter with the 3 ml volume was greater with the Respirgard II (p < 0 01) and was increased with the 6 ml volume with both nebulisers (p < 0 05).
The results of lung function tests are shown in table 4. The reductions in FEV1, forced vital capacity, and peak expiratory flow were larger with the 150 mg pentamidine dose and with the System 22 Mizer when the 3 ml nebuliser volume was used, though the differences were small and unlikely to be of clinical importance. Adverse effects were more frequent with the higher pentamidine dose and the System 22 Mizer; none was severe, however, and all patients were able to tolerate both the 50 and the 150 mg doses of pentamidine with both nebulisers.
Discussion
Nebulised pentamidine is used as a site specific treatment to prevent the recurrence of pneumocystis pneumonia, and has a low in- cidence of systemic adverse effects even with high doses. Nebuliser treatment is time consuming, however, and reducing the nebulisation time by increasing the drug concentration or reducing the volume to be nebulised is appealing. Side effects are more frequent with high pentamidine concentrations, and small nebuliser fluid volumes reduce the efficiency of delivery. The "dead volume" of fluid that remains attached to the baffles and other internal components in the nebuliser is variable but may be as much as half of the initial volume.8 Thus pentamidine delivery must be measured for each nebuliser, dose of pentamidine, and initial nebuliser volume to ensure that adequate lung deposition is achieved. In the absence of radiolabelled pentamidine, a marker must be used that does not affect the output characteristics of the nebuliser and faithfully repoduces the movement of pentamidine in the aerosol cloud. Work from our own department"2 and elsewhere'4 suggests that 99nTc HSA is suitable for this purpose. Using this marker of pentamidine deposition and the methods described above we have studied the performance of the System 22 Mizer and Respirgard II nebulisers with two doses of pentamidine and two volumes in the nebuliser. The percentage deposition (total deposition/nebuliser dose x 100) was from 2 7°o to 2-9% with the Respirgard II, and from 4.60o to 7.4% with the System 22 Mizer, depending on the dose and volume in the nebuliser. Under identical conditions ofuse the System 22 Mizer deposits 1 -62-6 times as much pentamidine in the lungs as does the Respirgard II. This is consistent with the greater retention of pentamidine in the inhalation apparatus and exhalation filter of the Respirgard II.
Increasing the volume in the nebuliser from 3 to 6 ml increased the nebuliser output and the pulmonary deposition of pentamidine with the System 22 Mizer but not with the Respirgard II. A substantial increase in the nebulisation time was found with both nebulisers. The increasing slope of the activity-time curve during inhalation of 50 mg pentamidine in 6 ml solution via the Respirgard II suggests that pentamidine concentration in the nebuliser cloud increases with time. This could be caused by evaporation of water associated with the prolonged nebulisation period, resulting in concentration of drug in the "dead volume" and thus reducing the efficiency of the nebuliser. This effect is less pronounced with the smaller volume and the System 22 Mizer because of the short nebulisation periods required.
Non-pulmonary deposition, changes in lung function, and adverse effects were greater with the System 22 Mizer, but the nebuliser could be tolerated by all the subjects. The increased deposition in the upper respiratory tract and central lung region is to be expected in view of the larger aerosol particles. Adverse effects were less frequent with the higher volume offill despite the increased deposition in the upper and lower respiratory tract. This suggests that these adverse effects are related to the concentration and rate of deposition of the pentamidine solution rather than the total dose delivered.
As the minimum lung dose of pentamidine giving adequate therapeutic or prophylactic response is not known, we must await the results of trials using different doses of pentamidine and different nebulisers before designing trials or recommending doses. Leoung et al" have shown that 150 mg pentamidine twice monthly, or 300 mg monthly, in 6 ml solution nebulised via a Respirgard II nebuliser provides adequate prophylaxis against pneumocystis pneumonia. Our results suggest that this represents a lung dose of about 9 mg each month. Similar lung doses can be achieved by nebulising lower doses of the drug via more efficient apparatus, such as the System 22 Mizer. This approach would be less costly and time consuming, but may be associated with more frequent local symptoms. Alternatively, if the same nebuliser dose of pentamidine were given via the System 22 Mizer, better prophylaxis may be achieved, particularly in view of its superior deposition in the upper lung, a common site for recurrence of pneumocystis pneumonia. Possibly other nebulisers or conditions of use would further improve pulmonary deposition and acceptability to patients.
We recommend that pulmonary pentamidine deposition is measured under the conditions used in the clinical trials currently in progress to allow a more informed comparison of their results. Knowledge of lung deposition is mandatory if the most appropriate dose, solution volume, and nebuliser for pentamidine administration are to be selected.
